top of page

EC approves AstraZeneca’s Brilique at a new 60mg dose

The European Commission (EC) has granted marketing authorisation to AstraZeneca’s Brilique (ticagrelor) at a new 60mg dose for the treatment of patients who have suffered a heart attack at least one year prior and are at high risk of developing a further atherothrombotic event.


Click on this link for more information.


source: http://www.europeanpharmaceuticalreview.com/39023/news/industry-news/ec-approves-astrazenecas-brilique-at-a-new-60mg-dose/

#Pharmanews

Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page